Akebia Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for AKBA, updated each market day.
AKBA AI Sentiment
AI sees no strong directional signal for Akebia Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Akebia Therapeutics, Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Sector
Exchange
Market Cap
$377,709,726
Cap Tier
Employees
194
Headquarters
CAMBRIDGE, MA
Listed Since
March 20, 2014
Website
AKBA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AKBA Volatility
Akebia Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
